Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
23:53:44 EST Fri 06 Feb 2026
Enter Symbol
or Name
USA
CA



Q:LXRX - LEXICON PHARMACEUTICALS INC - https://www.lexpharma.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
LXRX - Q0.61.16·1.310.21.23+0.054.22,085.82,3844,7001.20  1.27  1.201.83  0.283619:53:4217:1715 min RT 2¢

Recent Trades - Last 10 of 4700
Time ETExPriceChangeVolume
19:53:42Q1.230.0591
18:55:45Q1.270.0969
18:35:58Q1.260.0897
18:09:13Q1.26710.087160
18:08:23Q1.270.0910
17:34:06Q1.26970.089797
17:26:39Q1.250.07360
16:57:59Q1.250.07800
16:32:51Q1.24620.0662200
16:10:04Q1.230.051

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-02-06 17:17U:LXRXNews ReleaseLexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement
2026-01-30 02:50U:LXRXNews ReleaseLexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement
2026-01-29 16:31U:LXRXNews ReleaseLexicon Announces Proposed Public Offering of Common Stock
2026-01-23 08:30U:LXRXNews ReleaseLexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary
2026-01-21 08:30U:LXRXNews ReleaseLexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain
2026-01-12 07:30U:LXRXNews ReleaseLexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference
2026-01-09 08:30U:LXRXNews ReleaseLexicon Pharmaceuticals Publishes "Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain"
2026-01-07 08:30U:LXRXNews ReleaseLexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
2025-12-10 08:30U:LXRXNews ReleaseLexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851
2025-12-05 08:30U:LXRXNews ReleaseClinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum
2025-11-25 08:30U:LXRXNews ReleaseLexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences
2025-11-11 08:30U:LXRXNews ReleaseLexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare Conference
2025-11-08 14:30U:LXRXNews ReleaseClinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025
2025-11-06 07:30U:LXRXNews ReleaseLexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates
2025-11-04 08:30U:LXRXNews ReleaseData Demonstrating Unique Benefits of Sotagliflozin in Diverse Patient Populations will be Presented at the Hypertrophic Cardiomyopathy Society and American Heart Association's Sessions 2025 in New Orleans
2025-10-30 08:30U:LXRXNews ReleaseLexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
2025-10-14 08:00U:LXRXNews ReleaseLexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit
2025-10-08 07:59U:LXRXNews ReleaseLexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain
2025-09-22 16:00U:LXRXNews ReleaseLexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista(TM) in Type 1 Diabetes
2025-09-17 07:00U:LXRXNews ReleasePilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings